FDA Alerts

FDA Approves New Topical Psoriasis Therapy
The FDA has recently approved a new once-daily topical treatment for adult patients with plaque psoriasis.
FDA Approves IL-23 Inhibitor for PsA
The FDA approved guselkumab, a selective IL-23 inhibitor, for the treatment of adult patients with active psoriatic arthritis.
FDA Approves New Topical Rosacea Therapy
The FDA has approved a new topical foam medication for the treatment of inflammatory lesions caused by rosacea in adults.
FDA Approves First Treatment for Photo-Toxic Reactions
The FDA approved a new therapy to increase pain-free light exposure in adult patients with a history of phototoxic reactions caused by erythropoietic protoporphyria.
FDA Approves New Treatment for Facial and Truncal Acne
The FDA recently approved a new topical retinoid for the treatment of acne on both the face and the trunk.
FDA Approves Expanded Indication of Topical Acne Treatment
The FDA approved the expanded indication of topical dapsone 7.5% gel for the treatment of acne vulgaris in patients aged 9 to 11 years.
FDA Approves Therapy for Oral Ulcers Associated with Rare Disease
The FDA approved a new treatment option for patients with oral ulcers associated with Behçet disease.
FDA Approves New Option for Chronic Rhinosinusitis With Nasal Polyps
The FDA has approved the first treatment option for chronic, inadequately controlled rhinosinusitis with nasal polyps.
FDA Approves New Psoriasis Treatment for Adolescents
The FDA approved a new foam treatment for adolescents with plaque psoriasis on the scalp and body.
FDA Approves Enbrel Biosimilar
The FDA has approved a second biosimilar to etanercept for the treatment of various autoimmune conditions.

Back to Top